Transaction details
According to a Form 4 filed with the Securities and Exchange Commission, Sono-Tek CORP (NASDAQ: SOTK) director Lawal Adeniyi purchased 2,400 shares of the company’s common stock on March 5, 2026. The shares were acquired at $4.12 each, producing a total outlay of $9,888. The filing also indicates that Adeniyi disposed of 2,400 Sono-Tek options in connection with the reported activity. The share purchase increased Adeniyi’s direct ownership stake in the company.
The reported purchase price of $4.12 per share was above the contemporaneous market quote of $3.98, as cited in public data accompanying the filing. Separately, valuation information from InvestingPro noted that the company may be undervalued when measured against its Fair Value analysis.
Company financial snapshot
Public data referenced in filings and analyst materials list Sono-Tek’s market capitalization at $63.21 million. InvestingPro Tips, as cited in the filing materials, indicate the company holds more cash than debt on its balance sheet and has been profitable over the last twelve months. For investors seeking expanded financial detail, a Pro Research Report covering Sono-Tek and more than 1,400 other U.S. equities is available through the stated research service.
Recent commercial and technical developments
Separately from the insider transaction, Sono-Tek announced it received a purchase order worth $820,000 for coating equipment. The order was placed through a subcontractor and is intended for use in the production of diagnostic medical devices. The equipment will be integrated into an automated manufacturing line and will support the deposition of a specialized electronically active layer, according to the company disclosure.
Sono-Tek also disclosed a technical collaboration with Diamond Quanta. The stated aim of the partnership is to embed Sono-Tek’s ultrasonic coating technology into Diamond Quanta’s manufacturing processes. The collaboration is described as intended to enhance thin-film deposition capabilities and multilayer integration in engineered diamond applications.
Analyst action
Oak Ridge Financial revised its price target for Sono-Tek stock from $7.75 to $8.50 and retained a Buy rating. The firm cited Sono-Tek’s increasing exposure to medical markets - specifically drug-eluting balloons, stents, and diagnostics - as a central factor supporting its maintained positive stance. Oak Ridge highlighted the recently disclosed purchase order and the technical collaboration with Diamond Quanta as evidence of the company’s ongoing efforts to diversify within the medical and advanced materials sectors.
What this means
The Form 4 filing documents an insider purchase that raised a director’s direct ownership and coincides with operational developments and an analyst update. Publicly cited financial indicators point to a company with modest market capitalization, a net cash position relative to debt, and profitability over the previous twelve months. Investors looking for additional financial analysis are directed to the referenced Pro Research Report and related research products.